ALL Clinical Trial
Official title:
Dose-escalation Sequention Cohort Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GNR-084 in Patients With Refractory or Relapse Acute Lymphoblastic B-cell Precursor Leukemia.
It is an open-label dose-escalating study in sequential cohorts to assess safety and pharmacokinetics of GNR-084.
Acute lymphoblastic leukemias (ALL) are a heterogeneous group of malignant clonal diseases of the blood system originating from precursor cells of hematopoiesis, predominantly of lymphoid differentiation. More than 7,200 new cases of ALL are diagnosed annually in the European Union (EU), with approximately 40% (approximately 3,000 cases) occurring in adults The main reason for the failure of treatment of acute B-cell lymphoblastic leukemias (B-ALL) is the primary refractoriness to chemical exposure and relapses of the disease, which actually occur in 40-50% of adult patients with ALL. The prognosis in these cases is regarded as extremely unfavorable. Escalation of the chemotherapeutic approach is associated with the development of severe toxic infectious and hemorrhagic complications. The active substance of the preparation GNR-084 is a bispecific antibody to CD19 / CD3 in the BiMS format (bispecific IgG-like molecules). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05016947 -
Venetoclax Plus Inotuzumab for B-ALL
|
Phase 1 | |
| Recruiting |
NCT05009537 -
Optical Genome Mapping in Hematological Malignancies
|
||
| Terminated |
NCT01230788 -
Rituximab for Patients With Relapsed Acute Lymphoblastic Leukemia
|
N/A | |
| Completed |
NCT00333190 -
CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation
|
N/A | |
| Recruiting |
NCT05461625 -
ACL Reconstruction With/Without ALL Reconstruction
|
N/A | |
| Recruiting |
NCT02990572 -
Amish/Mennonite Research Contact Registry
|
||
| Completed |
NCT02631993 -
Photochemotherapy and Graft-versus-leukemia in Acute-leukemia
|
N/A | |
| Completed |
NCT00863148 -
Allogeneic Stem Cell Transplant With Clofarabine, Busulfan and Antithymocyte Globulin (ATG) for Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS) or Acute Lymphoblastic Leukemia (ALL)
|
Phase 2 | |
| Not yet recruiting |
NCT05592470 -
commd7 Gene Expression in ALL
|
||
| Recruiting |
NCT02861209 -
Collaborative Network to Take Responsibility for Oral Anticancer Therapy
|
N/A | |
| Completed |
NCT01012492 -
Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT
|
Phase 2 | |
| Recruiting |
NCT04644016 -
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
|
Phase 2 | |
| Recruiting |
NCT06131801 -
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
|
||
| Recruiting |
NCT05476770 -
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
|
Phase 1 | |
| Recruiting |
NCT03571321 -
Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic Leukemia
|
Phase 1 | |
| Recruiting |
NCT05414162 -
Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy
|
||
| Active, not recruiting |
NCT03154346 -
Project Baseline Health Study
|
||
| Terminated |
NCT01532635 -
A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives
|
Phase 2 | |
| Completed |
NCT01319864 -
POETIC Plerixafor as a Chemosensitizing Agent for Relapsed Acute Leukemia and MDS in Pediatric Patients
|
Phase 1 | |
| Completed |
NCT00013533 -
Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies
|
Early Phase 1 |